Hep B, C Could Be Eliminated As Public Health Threats by 2030

Share this content:
Hep B, C Could Be Eliminated As Public Health Threats by 2030
Hep B, C Could Be Eliminated As Public Health Threats by 2030

THURSDAY, March 30, 2017 (HealthDay News) -- Hepatitis B and C could be eliminated as serious public health problems in the United States by 2030, according to a report from the National Academies of Sciences, Engineering, and Medicine.

Brian L. Strom, M.D., M.P.H., from Rutgers University in Newark, N.J., and colleagues address potential approaches to reducing mortality caused by hepatitis B and C.

The researchers note that morbidity and mortality from viral hepatitis could be eliminated as serious public health issues by 2030, thereby preventing nearly 90,000 deaths. The tools are already available to prevent these deaths and include vaccination for hepatitis B and treatment of hepatitis C with short and easily tolerable courses of medications. The number of deaths from hepatitis B could be halved by 2030, averting 60,000 deaths, by diagnosing 90 percent of the nation's chronic hepatitis B patients, bringing 90 percent of those to care, and treating 80 percent of those with indications for treatment. Treating all patients with chronic hepatitis C would reduce new infections by about 90 percent by 2030, and reduce hepatitis C deaths by 65 percent. These actions could avert 28,800 deaths by 2030.

"Viral hepatitis is simply not a sufficient priority in the United States," Strom said in a statement. "Despite being the seventh leading cause of death in the world -- and killing more people every year than HIV, road traffic accidents, or diabetes -- viral hepatitis accounts for less than 1 percent of the National Institutes of Health research budget."

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »